Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface

Anticancer Research

Volumn 20, Issue 5, 2000, Pages 3293-3299

  Nio, Y ^a   Hirahara, N ^a   Minari, Y ^a   Iguchi, C ^a   Yamasawa, K ^a   Toga, T ^a   Tamura, K ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Antigen modulation; Cisplatin; MHC; Tumor vaccine

Indexed keywords

CISPLATIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNOMODULATION; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL FRACTIONATION; CISPLATIN; FLOW CYTOMETRY; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS II; LYMPHOCYTE DEPLETION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PLASMACYTOMA; SOLUBILITY; T-LYMPHOCYTES; VACCINATION;

EID: 0033789334     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum (II)
2. Enhancement of natural killer cytotoxicity by cis-Diamminedichloroplatinum (II) in vivo and in vitro
3. Activation of human NK cells and monocytes with cisplatin in vitro
4. Immunity against MOPC-104E plasmacytoma: Effects of tumor size and time post therapy on in vivo tumor immunity
5. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC- 104E plasmacytoma
6. Suppression by cytosine arabinoside of serum-blocking factors of cell-mediated immunity to syngeneic transplants of mouse mammary tumors
7. Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice
8. Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo
9. Increased release of interleukin-1 and tumor necrosis factor by interleukin-2 induced lymphokine-activated killer cells in the presence of cisplatin and FK-565
10. Studies on the release of interleukin-1 (IL-1), tumor necrosis factor (TNF) and lysozyme from human non-adherent mononuclear cells (nMNC) in vitro after treatment with cisplatin and other biological modifiers
11. Lymphocytes anticancer chemo-sensitivity testing in vitro; An approach to predict immunosuppressive effect of anticancer agents
12. Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells
13. Antiblastic chemotherapy drugs up-modulate interferon-gamma receptor expression on human malignant T cells
14. Cis-diamminedichloroplatinum (II) augments expression of tumor-associated antigens on human gastric cancer cell line KATO- 3 and increases susceptibility and binding of tumor cells to various cytotoxic effector cells
15. Effects of splenectomy on pulmonary metastasis and growth of SC 42 carcinoma transplanted into mouse liver
16. Modulation by cis-diammine-dichloroplatinum (II) of the susceptibilities of human T24 lined and fleshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells
17. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells